### ğŸ«  Valvular Heart Disease: Mitral Regurgitation Severity Assessment

#### âœ… True Statements
1. **Transesophageal echocardiography (TEE)** or **cardiac magnetic resonance (CMR) imaging** are gold standard tests for evaluating the severity of **mitral regurgitation**.
2. **Transthoracic echocardiography (TTE)** is the first-line test for evaluating valvular heart disease but may be insufficient when clinical findings and imaging findings do not match.
3. A **discrepancy between clinical findings and TTE characterization** of **mitral regurgitation severity** warrants further testing with **TEE** or **CMR imaging**.
4. **Coronary angiography** is not a primary modality for evaluating **regurgitant valvular disease severity**.
5. **Treadmill stress testing** does not help define the severity of **regurgitant valvular disease** such as **mitral regurgitation**.
6. Referring for **transcatheter mitral valve repair** in a patient with **moderate mitral regurgitation** is premature; further assessment with **TEE** is necessary to clarify severity and mechanism.

#### ğŸ’¬ Extra
1. TEE provides improved imaging of the mitral valve structure and regurgitant jet, especially when TTE is inconclusive.
2. TTE may underestimate severity in cases with eccentric jets or poor acoustic windows.
3. Clinical signs suggesting severe regurgitation include **holosystolic murmur with radiation** and **loud second heart sound (S2)** indicating pulmonary hypertension.
4. Coronary angiography is more useful for assessing **valvular stenotic disease** or cardiac ischemia.
5. Stress testing is more appropriate in **mitral or aortic stenosis**, not regurgitant lesions.
6. TEE also helps determine the **mechanism of mitral regurgitation**, distinguishing **primary** from **secondary causes**.

#### ğŸ”· Tags
#Cardiology #AmbulatoryCare #PatientOver65 #ValvularHeartDisease #MitralRegurgitation #TEE #CMR #TTE

#### ğŸ“™ Reference
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;143:e72-e227. PMID: 33332150 doi:10.1161/CIR.0000000000000923

#### ğŸ†” Question ID
CVMCQ24121

#### ğŸ•’ Last Updated
January 2025

---

#### ğŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Valvular Heart Disease, Clinical Presentation and Evaluation of Mitral Regurgitation

---

### ğŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Mitral regurgitation** may arise from dysfunction of any portion of the **valve apparatus**, including the **annulus**, **leaflets**, **chordae tendineae**, **papillary muscles**, or **left ventricular (LV) free wall**.
2. **Primary mitral regurgitation** is caused by structural abnormalities of the mitral valve and is most commonly due to **mitral valve prolapse (myxomatous degeneration)**.
3. **Secondary mitral regurgitation** results from **ventricular dysfunction**, causing **papillary muscle displacement** and **leaflet tethering**, while the valve structure remains normal.
4. In **acute mitral regurgitation**, there may be **blunted murmur intensity** and **less prominent color flow** on echocardiography due to rapid pressure equalization between the **left atrium (LA)** and **left ventricle (LV)**.
5. **Chronic mitral regurgitation** leads to **volume overload**, resulting in **LV dilation**, **LA hypertension**, and possibly **pulmonary hypertension** and **right ventricular (RV) failure**.
6. **Physical examination** in chronic mitral regurgitation reveals a **blowing holosystolic murmur** at the apex, sometimes preceded by **systolic clicks** in **mitral valve prolapse**.
7. **Transthoracic echocardiography (TTE)** accurately assesses **mitral regurgitation severity**, and typical findings in primary disease may include **prolapse**, **Barlow syndrome**, or **chordal rupture** with **flail leaflet**.
8. **Severe primary mitral regurgitation** is defined by an **effective regurgitant orifice area â‰¥0.4 cmÂ²**, **regurgitant volume â‰¥60 mL**, or **vena contracta width â‰¥0.7 cm**.
9. If **TTE provides discordant or insufficient data**, further evaluation with **TEE** or **CMR imaging** is indicated.

#### ğŸ’¬ Extra
1. This includes both acute and chronic presentations with various anatomic disruptions.
2. Mitral valve prolapse affects about 2% of the U.S. population.
3. The valve structure is normal in secondary mitral regurgitation despite significant regurgitation.
4. Acute presentations may lack typical auscultatory or echocardiographic signs, making diagnosis challenging.
5. Chronic overload can lead to progressive cardiac remodeling and clinical heart failure.
6. The murmur varies based on leaflet motion, loading conditions, and severity.
7. TTE abnormalities in degenerative mitral disease help differentiate subtypes and surgical planning.
8. These objective echocardiographic criteria guide clinical and surgical decision-making.
9. Advanced imaging is especially valuable when clinical suspicion and echocardiographic findings are incongruent.
10. Valve staging refers to the ACC/AHA stages Aâ€“D for valvular heart disease.
11. The timing of serial imaging depends on both **lesion severity** and **ventricular response**.
12. Effective regurgitant orifice area (EROA), regurgitant volume, and regurgitant fraction are derived from Doppler echocardiography.
13. **Patients at risk for aortic stenosis** with a **maximum aortic velocity (V<sub>max</sub>) &lt;2 m/s** are classified as **stage A**.
14. **Mild aortic stenosis** (stage B) is defined by a **V<sub>max</sub> of 2.0â€“2.9 m/s** or **mean gradient &lt;20 mm Hg**.
15. **Moderate aortic stenosis** (stage B) is defined by a **V<sub>max</sub> of 3.0â€“3.9 m/s** or **mean gradient 20â€“39 mm Hg**.
16. **Severe aortic stenosis** (stage C1) is defined by a **V<sub>max</sub> â‰¥4.0 m/s**, **mean gradient â‰¥40 mm Hg**, and **aortic valve area â‰¤1.0 cmÂ²**.
17. **Very severe aortic stenosis** is defined by a **V<sub>max</sub> â‰¥5.0 m/s** or **mean gradient â‰¥60 mm Hg**.
18. Asymptomatic patients with **mild or moderate aortic stenosis** should receive **clinical evaluation yearly**.
19. **Echocardiography** should be performed every **3â€“5 years for mild** and **1â€“2 years for moderate aortic stenosis**.
20. Patients with **severe aortic stenosis (stage C1)** should have **echocardiography every 6â€“12 months**.
21. **Mild aortic regurgitation** (stage B) is defined by **vena contracta &lt;0.3 cm**, **effective regurgitant orifice area (EROA) &lt;0.10 cmÂ²**, **regurgitant volume &lt;30 mL/beat**, and **regurgitant fraction &lt;30%**, with **normal ejection fraction**.
21. **Moderate aortic regurgitation** (stage B) is defined by **vena contracta 0.3â€“0.6 cm**, **EROA 0.10â€“0.29 cmÂ²**, **regurgitant volume 30â€“59 mL/beat**, and **regurgitant fraction 30%â€“49%**.
22. **Severe aortic regurgitation** (stage C1) is defined by **vena contracta &gt;0.6 cm**, **EROA â‰¥0.30 cmÂ²**, **regurgitant volume â‰¥60 mL/beat**, and **regurgitant fraction â‰¥50%**.
23. **Echocardiography** should be performed every **3â€“5 years for mild**, **1â€“2 years for moderate**, and **6â€“12 months for severe aortic regurgitation**.
24. In **severe aortic regurgitation**, echocardiography may be performed **more frequently if the left ventricle is dilating**.
25. **Mild to moderate mitral stenosis** (stage B) is defined by **mitral valve area (MVA) &gt;1.5 cmÂ²** and **diastolic pressure half-time &lt;150 ms**.
26. **Severe mitral stenosis** (stage C1) is defined by **MVA 1.0â€“1.5 cmÂ²**, **diastolic pressure half-time â‰¥150 ms or â‰¥220 ms** in very severe stenosis, and **pulmonary artery systolic pressure (PASP) &gt;50 mm Hg**.
27. **Echocardiography** should be performed every **3â€“5 years for mild to moderate mitral stenosis**.
28. **Echocardiography** should be performed every **1â€“2 years for severe mitral stenosis** with **MVA 1.0â€“1.5 cmÂ²**.
29. **Echocardiography** should be performed **annually for MVA &lt;1.0 cmÂ²**.
30. **Mild mitral regurgitation** (stage A) is defined by **vena contracta &lt;0.3 cm**, **EROA &lt;0.20 cmÂ²**, **regurgitant volume &lt;30 mL/beat**, and **regurgitant fraction &lt;30%**.
31. **Moderate mitral regurgitation** (stage B) is defined by **vena contracta &lt;0.7 cm**, **EROA 0.20â€“0.39 cmÂ²**, **regurgitant volume 30â€“59 mL/beat**, and **regurgitant fraction 30%â€“49%**.
32. **Severe mitral regurgitation** (stage C) is defined by **vena contracta â‰¥0.7 cm**, **EROA â‰¥0.40 cmÂ²**, **regurgitant volume â‰¥60 mL/beat**, and **regurgitant fraction â‰¥50%**.
33. **Echocardiography** should be performed every **3â€“5 years for mild**, **1â€“2 years for moderate**, and **6â€“12 months for severe mitral regurgitation**.
34. In **severe mitral regurgitation**, echocardiography may be performed **more frequently if the left ventricle is dilating**.

#### ğŸ”· Tags
#Cardiology #ValvularHeartDisease #MitralRegurgitation #PrimaryMR #SecondaryMR #TEE #CMR #Echocardiography #Cardiology #ValvularHeartDisease #AorticStenosis #AorticRegurgitation #MitralStenosis #MitralRegurgitation #Echocardiography #Surveillance #AsymptomaticVHD

#### ğŸ“™ Reference
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. *J Am Coll Cardiol*. 2021;77:e25â€“e197. doi:[10.1016/j.jacc.2020.11.018](https://doi.org/10.1016/j.jacc.2020.11.018). PMID: [33342586](https://pubmed.ncbi.nlm.nih.gov/33342586)

---

### ğŸ–¼ï¸ Supplemental Figures and Videos

<figure>
  <img src="Echocardiograms Demonstrating Secondary Mitral Regurgitation in a Patient With Previous Inferior Myocardial Infarction.jpg" alt="Echocardiograms Demonstrating Secondary MR">
  <figcaption><strong>Echocardiograms Demonstrating Secondary Mitral Regurgitation in a Patient With Previous Inferior Myocardial Infarction</strong><br>
  Tethering of the posterior leaflet (arrow, left panel) is present as a result of the previous infarction and left ventricular remodeling. Mitral regurgitation (arrow, right panel) is evident on color flow imaging. Ao = ascending aorta; LA = left atrium; LV = left ventricle.</figcaption>
</figure>

<figure>
  <img src="Echocardiogram Showing Mitral Valve Prolapse.jpg" alt="Echocardiogram Showing Mitral Valve Prolapse">
  <figcaption><strong>Echocardiogram Showing Mitral Valve Prolapse</strong><br>
  Echocardiogram showing normal opening of the mitral valve (arrow, top left panel), which then prolapses into the left atrium during systole (arrows, top right panel). In a different patient with myxomatous degeneration, a flail portion of the posterior mitral valve is present (bottom panels); torn chordae are seen (arrowheads), leading to severe regurgitation seen on color flow imaging (arrow, bottom right panel). Ao = ascending aorta; LA = left atrium; LV = left ventricle.</figcaption>
</figure>

<figure>
  <video controls width="640">
    <source src="Rheumatic Mitral Regurgitation.mp4" type="video/mp4">
    Your browser does not support the video tag.
  </video>
  <figcaption><strong>Rheumatic Mitral Regurgitation</strong><br>
  The carotid pulse is normal. In the mitral area, S1 is obscured by a high-frequency grade 2 holosystolic murmur. The murmur begins with mitral closure and continues up to and through aortic closure.<br>
  This video is used with permission from the Michael S. Gordon Center for Simulation and Innovation in Medical Education, University of Miami Miller School of Medicine, Miami, Florida. https://gordoncenter.miami.edu</figcaption>
</figure>

<figure>
  <video controls width="640">
    <source src="Mitral Valve Prolapse.mp4" type="video/mp4">
    Your browser does not support the video tag.
  </video>
  <figcaption><strong>Mitral Valve Prolapse</strong><br>
  The carotid pulsation is normal. In the mitral area, midsystolic clicks and a high-frequency grade 3 late systolic crescendo murmur are present. Standing decreases venous return, reduces ventricular size, and results in earlier and more marked prolapse of the mitral valve leaflet, and earlier clicks and murmur.<br>
  This video is used with permission from the Michael S. Gordon Center for Simulation and Innovation in Medical Education, University of Miami Miller School of Medicine, Miami, Florida. https://gordoncenter.miami.edu</figcaption>
</figure>

### ğŸ“Š Supplemental Table

<table>
  <caption><strong>Serial Evaluation of Asymptomatic Patients With Left-Sided Valvular Conditions</strong></caption>
  <thead>
    <tr>
      <th>Condition</th>
      <th>Factors Considered</th>
      <th>VHD Stage</th>
      <th>Lesion Severity</th>
      <th>Frequency of Evaluation</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td rowspan="4"><strong>Aortic Stenosis</strong></td>
      <td rowspan="4">Stenosis severity; rate of progression; LV systolic function; ascending aorta dilation if associated with bicuspid aortic valve</td>
      <td>A</td>
      <td>At risk (V<sub>max</sub> &lt;2 m/s)</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td>B</td>
      <td>Mild (V<sub>max</sub> 2.0â€“2.9 m/s or mean gradient &lt;20 mm Hg)</td>
      <td>Clinical evaluation yearly; echo every 3â€“5 y</td>
    </tr>
    <tr>
      <td>B</td>
      <td>Moderate (V<sub>max</sub> 3.0â€“3.9 m/s or mean gradient 20â€“39 mm Hg)</td>
      <td>Clinical evaluation yearly; echo every 1â€“2 y</td>
    </tr>
    <tr>
      <td>C1</td>
      <td>Severe (V<sub>max</sub> â‰¥4 m/s or mean gradient â‰¥40 mm Hg, AVA typically â‰¤1.0 cmÂ²)<br>Very severe (V<sub>max</sub> â‰¥5 m/s or mean gradient â‰¥60 mm Hg)</td>
      <td>Clinical evaluation yearly; echo every 6â€“12 mo</td>
    </tr>
    <tr>
      <td rowspan="3"><strong>Aortic Regurgitation</strong></td>
      <td rowspan="3">Regurgitation severity; rate of progression; LV ejection fraction; LV chamber size; ascending aorta dilation if bicuspid aortic valve</td>
      <td>B</td>
      <td>Mild (VC &lt;0.3 cm, ERO &lt;0.10 cmÂ², RV &lt;30 mL/beat, RF &lt;30%); normal EF</td>
      <td>Clinical evaluation yearly; echo every 3â€“5 y</td>
    </tr>
    <tr>
      <td>B</td>
      <td>Moderate (VC 0.3â€“0.6 cm, ERO 0.10â€“0.29 cmÂ², RV 30â€“59 mL/beat, RF 30%â€“49%)</td>
      <td>Clinical evaluation yearly; echo every 1â€“2 y</td>
    </tr>
    <tr>
      <td>C1</td>
      <td>Severe (VC &gt;0.6 cm, ERO â‰¥0.3 cmÂ², RV â‰¥60 mL/beat, RF â‰¥50%)</td>
      <td>Clinical evaluation every 6â€“12 mo; echo every 6â€“12 mo, more frequently for dilating LV</td>
    </tr>
    <tr>
      <td rowspan="2"><strong>Mitral Stenosis</strong></td>
      <td rowspan="2">Stenosis severity</td>
      <td>B</td>
      <td>Mild and moderate (MVA &gt;1.5 cmÂ², diastolic pressure half-time &lt;150 ms)</td>
      <td>Clinical evaluation yearly; echo every 3â€“5 y</td>
    </tr>
    <tr>
      <td>C1</td>
      <td>Severe (MVA 1.0â€“1.5 cmÂ², diastolic pressure half-time â‰¥150 ms or â‰¥220 ms with very severe stenosis, PASP &gt;50 mm Hg)</td>
      <td>Clinical evaluation yearly; echo every 1â€“2 y for MVA 1.0â€“1.5 cmÂ², every year for MVA &lt;1.0 cmÂ²</td>
    </tr>
    <tr>
      <td rowspan="3"><strong>Mitral Regurgitation</strong></td>
      <td rowspan="3">Regurgitation severity; rate of progression; EF; LV chamber size</td>
      <td>A</td>
      <td>Mild (VC &lt;0.3 cm, ERO &lt;0.2 cmÂ², RV &lt;30 mL/beat, RF &lt;30%)</td>
      <td>Clinical evaluation yearly; echo every 3â€“5 y</td>
    </tr>
    <tr>
      <td>B</td>
      <td>Moderate (VC &lt;0.7 cm, ERO 0.2â€“0.39 cmÂ², RV 30â€“59 mL/beat, RF 30%â€“49%)</td>
      <td>Clinical evaluation yearly; echo every 1â€“2 y</td>
    </tr>
    <tr>
      <td>C</td>
      <td>Severe (VC â‰¥0.7 cm, ERO â‰¥0.4 cmÂ², RV â‰¥60 mL/beat, RF â‰¥50%)</td>
      <td>Clinical evaluation every 6â€“12 mo; echo every 6â€“12 mo, more frequently for dilating LV</td>
    </tr>
  </tbody>
</table>

<p><em>
AVA = aortic valve area; echo = echocardiography; EF = ejection fraction; ERO = effective regurgitant orifice; LV = left ventricular; LVESD = left ventricular end-systolic dimension; MVA = mitral valve area; PASP = pulmonary artery systolic pressure; RF = regurgitant fraction; RV = regurgitant volume; VC = vena contracta width; VHD = valvular heart disease; V<sub>max</sub> = maximum aortic jet velocity.
</em></p>

<p><strong>Reference:</strong> Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 2021;77:e25â€“e197. <a href="https://doi.org/10.1016/j.jacc.2020.11.018">doi:10.1016/j.jacc.2020.11.018</a> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33342586">33342586</a>
</p>
